Evan King
Plus aucun poste en cours
Profil
Evan King worked as an Associate Director at Gilead Sciences, Inc., a Director-Pharmaceutical Project Management at Allos Therapeutics, Inc., an Executive Director-Business Operations at SomaLogic Operating Co., Inc., and a Chief Operating Officer at CPC Clinical Research.
He obtained an undergraduate degree from the University of California, Santa Barbara.
Anciens postes connus de Evan King
| Sociétés | Poste | Fin |
|---|---|---|
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | - |
CPC Clinical Research
 CPC Clinical Research Miscellaneous Commercial ServicesCommercial Services CPC Clinical Research is a research organization that specializes in clinical trial design and management. The non-profit company is based in Aurora, CO. | Directeur des opérations | - |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
SomaLogic Operating Co., Inc.
 SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Directeur des opérations | - |
Formation de Evan King
| University of California, Santa Barbara | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Health Technology |
CPC Clinical Research
CPC Clinical Research Miscellaneous Commercial ServicesCommercial Services CPC Clinical Research is a research organization that specializes in clinical trial design and management. The non-profit company is based in Aurora, CO. | Commercial Services |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |